New anti-AIDS drug Selavino developed by Chinese scientists has been approved by China's State Drug Administration for clinical trials

Recently, theof theof the Anti-AIDSNew Drug(http:// developed by the ShanghaiMedicines(http://) Research Institute of the Chinese Academy of Sciences and the Institute agreed to conduct a clinical trial on May 5, 2019,by the ClinicalTrial(http:// issued by the China Nationalmedicine http://
s.aregulatory authorityearly basic research work was published in the leading international journalS Science and the leading journal of pharmaceutical chemistry, Journal of Medicinal Chemistrythe project is currently preparing for clinical Phase I studiesIf the research and development is successful, it will better meet the clinical drug demand of AIDS patients 　　According to reports, Serravino is China's first approved into clinical research CCR5 receptor antagonists, has been 13th Five-Year "major new drug creation" science and technology major special projects, the Chinese Academy of Sciences strategic pilot science and technology special projects, as well as the Chinese Academy of Sciences independent deployment projects, Yunnan Provincial Science and Technology Department and other funds 　　First, through computer-aided drug design, using a drug design strategy based on structure and changing metabolic pathways, designing new structural type CCR5 antagonists, and using the highly synthetic (http:// technology to carry out multi-wheel structural transformation and drug optimization of CCR5 antagonists, the only clinical drug available for CCR5 targets was analyzed Maramarano and a number of CCR5 antagonists and CCR5 receptor crystal complex structure, CCR5 antagonist anti-HIV activity screening and research, on the basis of which in-depth structural modification, efficacy evaluation and drug optimization, found a new skeleton of CCR5 antagonist candidate drug - Serravino 　　Preclinical studies show that Seravino has better antagonistic activity on CCR5 receptors than Maramarano, and has better inhibitory activity and treatment index for a variety of HIV, clinical and drug-resistant strains than Maramarano or equivalent; 　　At present, Serravino and its range of compounds have been the United States, Europe, Russia, South Korea and Australia and other countries of the patent (http:// authorized